---
permalink: /
title: ""
excerpt: ""
author_profile: true
redirect_from: 
  - /about/
  - /about.html
---

{% if site.google_scholar_stats_use_cdn %}
{% assign gsDataBaseUrl = "https://cdn.jsdelivr.net/gh/" | append: site.repository | append: "@" %}
{% else %}
{% assign gsDataBaseUrl = "https://raw.githubusercontent.com/" | append: site.repository | append: "/" %}
{% endif %}
{% assign url = gsDataBaseUrl | append: "google-scholar-stats/gs_data_shieldsio.json" %}

<span class='anchor' id='简介'></span>

刘旭昇，男，1994年1月生，湖北医药学院医学影像与核医学硕士，太和医院核医学科主治医师/助教。主要从事核医学SPECT/CT、PET/CT分子功能影像诊断；肿瘤分子靶向功能影像诊断和治疗研究等。参与国家自然科学基金1项，主持省级课题1项。曾荣获“十堰市优秀共青团干部”、“湖北医药学院优秀共产党员”、“湖北医药学院杏林英才”和“十堰市太和医院医师节优秀初级医师”等多种称号。


在国内外期刊发表论文30余篇，近5年来以第一作者或通讯作者发表SCI论文20篇，累计影响因子近100分，<a href='https://scholar.google.com/citations?user=VnJ0pkYAAAAJ'>google scholar citations <strong><span id=total_cit>400+</span></strong></a> <a href='https://scholar.google.com/citations?user=VnJ0pkYAAAAJ'><img src="https://img.shields.io/endpoint?url={{ url | url_encode }}&logo=Google%20Scholar&labelColor=f6f6f6&color=9cf&style=flat&label=citations"></a>。


🔥主要研究方向：
基于糖酵解代谢重编程的肿瘤分子标志物识别与精准诊疗策略研究。

# 📒 自然科学项目
1. 湖北省肝癌精准诊疗临床医学研究中心，一般项目，2024LCOF08，RAB3B作为肝细胞癌预后生物标志物通过调控GPI介导糖酵解能力影响肿瘤进展的机制研究，2024.01.01至2025.12.31，1.0万元，在研，主持
2. 湖北医药学院附属太和医院，一般项目，2024JJXM087，肺腺癌中 DARS2 的表达及其与肿瘤进展的机制研究，2024-01-01至2025-12-31，0.8万元，在研，主持
3. 湖北省教育厅, 优秀中青年科技创新团队, T2020025, 基于HSCs靶向DNA适配体的肝纤维化诊、疗一体化体系建立的研究, 2020-01至2023-12, 20万元, 已结题, 参加
4. 湖北医药学院附属太和医院, 院级项目, 2023JJXM113, 探索 METTL3 在食管癌糖酵解中的作用及其与 lncRNA SNHG1/miR-101-3p ceRNA 网络的相互作用, 2023-01-01至2024-12-31, 0.8万元, 已结题, 主持
5. 湖北医药学院附属太和医院, 院级项目, 2022JJXM007, LncRNAKDM7A-DT 作为 ceRNA 调控miR-101-3p 靶向 METTL3 参与食管癌增殖和糖酵解的机制及分子影像学研究, 2022-01-01至2023-12-31, 0.8万元, 已结题, 主持
6. 湖北医药学院附属太和医院, 院级项目, 2021JJXM006, miR-212-5p 通过靶向 m6A 甲基化转移酶METTL3 抑制食管癌细胞增殖、侵袭和能量代谢的机制研究, 2021-01-01至2022-12-31, 0.8万元, 已结题, 主持
7. 湖北医药学院, 研究生科技创新项目, YC2019039, 肝癌靶向载体scrAAV3介导基因治疗可视化的实验研究, 2019-03至2020-06, 2万元, 已结题, 主持
8. 国家自然科学基金委员会, 青年项目, 81401447, 心肌特异性启动子引导的多模态报告基因显像活体监测干细胞移植治疗缺血性心脏疾病的显像研究, 2015-01至2017-12, 23万元, 已结题, 参加

# 📝 代表性成果 
1. **Liu X S**, Xu Y, Dai L S, et al. The potential of MCM8 as a biomarker in esophageal carcinoma: a comprehensive analysis integrating m6a methylation and angiogenesis[J/OL]. European Journal of Medical Research, 2025, 30(1): 373. DOI:10.1186/s40001-025-02541-3.
2. **Liu X S**, Pei Z J. 18F-FDG PET/CT in the diagnosis and treatment of atypical extensive skin lesions in extranodal natural killer/T-cell lymphoma, nasal type: a case report[J/OL]. Frontiers in Oncology, 2025, 15. DOI:10.3389/fonc.2025.1480661.
3. **Liu X S**, Xie J, Wu R M, et al. Expression patterns of MCM8 in lung adenocarcinoma and its correlation with key biological processes[J/OL]. European Journal of Medical Research, 2025, 30(1): 149. DOI:10.1186/s40001-025-02407-8.
4. Liu Z Y, Yuan L L, Gao Y, Zhang Y, Zhang Y H, Yang Y, Chen Y X, **Liu X S**, Pei Z J. SSB expression is associated with metabolic parameters of 18F-FDG PET/CT in lung adenocarcinoma and can improve diagnostic efficiency[J/OL]. Heliyon, 2024, 10(22): e38702. DOI:10.1016/j.heliyon.2024.e38702.
5. **Liu X S**, Chen Y L, Chen Y X, et al. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers[J/OL]. Scientific Reports, 2024, 14(1): 9881. DOI:10.1038/s41598-024-60581-x.
6. **Liu X S**, Zhang Y, Liu Z Y, et al. METTL3 as a novel diagnosis and treatment biomarker and its association with glycolysis, cuproptosis and ceRNA in oesophageal carcinoma[J/OL]. Journal of Cellular and Molecular Medicine, 2024, 28(6): e18195. DOI:10.1111/jcmm.18195.
7. **Liu X S**, Liu Z Y, Zeng D B, et al. Functional enrichment analysis reveals the involvement of DARS2 in multiple biological pathways and its potential as a therapeutic target in esophageal carcinoma[J/OL]. Aging-us, 2024, 16(4): 3934-3954. DOI:10.18632/aging.205569.
8. **Liu X S**, Chen Y X, Wan H B, et al. TRIP6 a potential diagnostic marker for colorectal cancer with glycolysis and immune infiltration association[J/OL]. Scientific Reports, 2024, 14(1): 4042. DOI:10.1038/s41598-024-54670-0.
9. Zhang Y H, **Liu X S**, Gao Y, et al. SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with 18F-FDG metabolic parameters[J/OL]. Lung Cancer, 2024, 188: 107449. DOI:10.1016/j.lungcan.2023.107449.
10. **Liu X S**, Liu C, Chen Y J, et al. Uterine Burkitt Lymphoma with Rare Extranodal Deposits in the Bone, Breast, and Sacral Canal: A Case Report[J/OL]. OncoTargets and Therapy, 2024, 17: 41-44. DOI:10.2147/OTT.S440228.
11. **Liu X S**, Zhang Y, Ming X, et al. SPC25 as a novel therapeutic and prognostic biomarker and its association with glycolysis, ferroptosis and ceRNA in lung adenocarcinoma[J/OL]. Aging-us, 2024, 16(1): 779-798. DOI:10.18632/aging.205418.
12. **Liu X S**, Yuan L L, Gao Y, et al. DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma[J/OL]. Journal of Translational Medicine, 2023, 21(1): 574. DOI:10.1186/s12967-023-04454-3.
13. **Liu X S**, Zeng J, Zhang Y H, et al. DARS2 is a prognostic biomarker and correlated with immune infiltrates and cuproptosis in lung adenocarcinoma[J]. American Journal of Cancer Research, 2023, 13(3): 818-834.
14. **Liu X S**, Liu C, Zeng J, et al. Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis[J/OL]. Frontiers in Pharmacology, 2022, 13: 1010879. DOI:10.3389/fphar.2022.1010879.
15. **Liu X S**, Yang J W, Zeng J, et al. SLC2A1 is a Diagnostic Biomarker Involved in Immune Infiltration of Colorectal Cancer and Associated With m6A Modification and ceRNA[J/OL]. Frontiers in Cell and Developmental Biology, 2022, 10: 853596. DOI:10.3389/fcell.2022.853596.
16. **Liu X S**, Kui X Y, Gao Y, et al. Comprehensive Analysis of YTHDF1 Immune Infiltrates and ceRNA in Human Esophageal Carcinoma[J/OL]. Frontiers in Genetics, 2022, 13: 835265. DOI:10.3389/fgene.2022.835265.
17. **Liu X S**, Wu R M, Wan H B, et al. Situs Inversus Totalis on 18F-FDG PET/CT: A Case Report and a Literature Review[J/OL]. Frontiers in Medicine, 2022, 9: 840795. DOI:10.3389/fmed.2022.840795.
18. **Liu X S**, Liu J M, Chen Y J, et al. Comprehensive Analysis of Hexokinase 2 Immune Infiltrates and m6A Related Genes in Human Esophageal Carcinoma[J/OL]. Frontiers in Cell and Developmental Biology, 2021, 9: 715883. DOI:10.3389/fcell.2021.715883.
19. **Liu X S**, Zhou L M, Yuan L L, et al. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis[J/OL]. Frontiers in Immunology, 2021, 12: 724741. DOI:10.3389/fimmu.2021.724741.
20. **Liu X S**, Gao Y, Wu L B, et al. Comprehensive Analysis of GLUT1 Immune Infiltrates and ceRNA Network in Human Esophageal Carcinoma[J/OL]. Frontiers in Oncology, 2021, 11: 665388. DOI:10.3389/fonc.2021.665388.
21. **Liu X S**, Gao Y, Liu C, et al. Comprehensive Analysis of Prognostic and Immune Infiltrates for E2F Transcription Factors in Human Pancreatic Adenocarcinoma[J/OL]. Frontiers in Oncology, 2021, 10: 606735. DOI:10.3389/fonc.2020.606735.
22. **Liu X S**, Yuan L L, Gao Y, et al. Overexpression of METTL3 associated with the metabolic status on 18F-FDG PET/CT in patients with Esophageal Carcinoma[J/OL]. Journal of Cancer, 2020, 11(16): 4851-4860. DOI:10.7150/jca.44754.
23. **Liu X**, Huang H, Gao Y, et al. Visualization of gene therapy with a liver cancer-targeted adeno-associated virus 3 vector[J/OL]. Journal of Cancer, 2020, 11(8): 2192-2200. DOI:10.7150/jca.39579.

# 📚 教研项目
1. 湖北医药学院研究生院，教育教学研究项目，YJ2025082，基于OBE理念的BOPPPS教学模式在核医学专业研究生科研能力培养的研究与实践，2025.04.10至2027.04.10，0.1万元，在研，主持
2. 湖北医药学院, 校级项目, YHJ2024011, 基于OBE理念的核医学专业型硕士研究生教育质量评价体系构建与实践, 2024-01-01至2025-12-31, 0.8万元, 在研, 主持

# 📄 专利
1. 高燕, 裴之俊, 刘旭昇. 一种18F-FDG PET/CT代谢参数在构建相应肿瘤预测系统方面的应用: ZL202210482438.2[P]. 2025-04-08. 已授权

# 🎖 竞赛获奖
1. 2024年第十六届中南六省（区）核医学学术交流会《核医学分子影像医师阅片竞赛》三等奖
2. 2023年“襄十随神”城市群第二届自然科学优秀学术论文成果已发表类三等奖
3. 2023年“襄十随神”城市群第二届自然科学优秀学术论文成果已发表类二等奖
4. 2023年“核医好医”PET/CT全国病例大赛(中部赛区)探索之星奖
5. 2022年“襄十随神”城市群首届自然科学优秀学术论文成果已发表类三等奖

# 👑 个人荣誉
1. 2022年十堰市太和医院医师节“优秀初级医师”
2. 2020年湖北医药学院2019年度“十佳青年”
3. 2020年湖北医药学院2019年度“杏林英才”
4. 2020年湖北医药学院研究生院2020届“优秀毕业生标兵”
5. 2016年湖北医药学院药护学院2016届“优秀毕业生”
6. 2015年湖北医药学院2015年度优秀共产党员
7. 2014年湖北医药学院2014年度优秀共产党员
8. 2013年湖北省大中专学生志愿者暑期“三下乡”社会实践活动“先进个人”
9. 2013年十堰市“优秀共青团干部”

# 👨‍🎓 学术任职
1. 2025年Medicine Advances杂志青年编委
2. 2023年Cancer Advances杂志青年编委

# 📖 教育经历
- 湖北医药学院；硕士；2017.09-2020.06
- 湖北医药学院药护学院；本科；2012.09-2016.06 



